General Information |
Summary |
To evaluate the safety and tolerability of MA09-hRPE cellular therapy in patients with advanced dry AMD To evaluate the safety of the surgical procedures when used to implant MA09-hRPE cells To assess the number of hRPE cells to be transplanted in future studies To evaluate on an exploratory basis potential efficacy endpoints to be used in future studies of MA09-hRPE cellular therapy. |
Clinical trials phase |
Phases 1/2 |
Start date (estimated) |
2012-09-01 |
End date (estimated) |
2016-04-30 |
Clinical feature |
Label |
atrophic macular degeneration |
Link |
http://www.ebi.ac.uk/efo/EFO_1001492 |
Description |
Dry AMD is most common type of macular degeneration and affects 90% of the people who have the condition. In the dry form, there is a breakdown or thinning of the layer of retinal pigment epithelial cells (RPE) in the macula. No medical or surgical treatment is available for this condition. |
|
Administrative Information |
NCT number |
NCT01674829 |
ICTRP weblink |
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=NCT01674829 |
Other study identifiers |
|
Source weblink |
http://www.clinicaltrials.gov/ct2/show/NCT01674829 |
Regulatory body approval |
Name |
Korea Food and Drug Administration (KFDA) |
Country |
|
|
Public contact |
Email |
hunheekang@chamc.co.kr |
Public email |
hunheekang@chamc.co.kr |
First name |
Hunhee |
Last name |
Kang |
Country |
|
|
Sponsors |
CHABiotech CO., Ltd |
Cell Line |
Stem cell lines obtained from |
|